“…These patients display dysfunctional IL-17F and -17A/F (IL-17F mutations) or dysfunctional responses to IL-17A, -17A/F, and -17F (mutations in IL-17RA, -17RC, and ACT1). In patients with AD HIES (54)(55)(56)(57), AD STAT1 GOF (13, 18, 21, 27-29, 32, 35, 36, 38, 39, 41, 42, 45, 46, 49), or AR ROR-γ/γT deficiency (53), the development of IL-17A/F-producing T cells is impaired. Finally, patients with AR APS-1 have high titers of neutralizing auto-Abs against IL-17A and -17F (58,59).…”